RYTM Q4 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+175.7% YoY

Gross Profit

$21M86.7% margin

Operating Income

-$41M-170.3% margin

Net Income

-$42M-171.8% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$333M

Total Liabilities

$163M

Stockholders' Equity

$170M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$9M	+175.7%
Gross Profit	$21M	$8M	+170.6%
Operating Income	-$41M	-$42M	+2.0%
Net Income	-$42M	-$42M	+2.0%